Yumab spinoff Corat to develop COVID-19 drug

By The Science Advisory Board staff writers

June 17, 2020 -- Yumab has announced that the first financing round of its spinoff Corat Therapeutics will be used to advance the development of COVID-19 antibody drug candidates.

Corat will continue the preclinical development of the lead antibody drug candidate for COVID-19, which was identified using Yumab's discovery of fully human monoclonal antibodies that neutralized activity against live SARS-CoV-2. Corat's efforts are led by managing director Thomas Schirrmann, PhD.

Clinical development may begin by the end of 2020, according to the company.

Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy.
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.
Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating...
Pfizer, BioNTech start clinical trials for mRNA COVID-19 vaccine
Clinical trials for a COVID-19 mRNA vaccine developed by Pfizer and BioNTech began on May 5 with New York University Grossman School of Medicine...
Valo to develop pancoronavirus vaccine
Valo Therapeutics announced that it is working on the development of a potential COVID-19 vaccine with applications across future pandemics.

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter